Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (Tine Hajdinjak) .

1 - 2 / 2
Na začetekNa prejšnjo stran1Na naslednjo stranNa konec
1.
Evaluation of safety and analgesic consumption in patients with advanced cancer treated with zoledronic acid
Andrej Kmetec, Tine Hajdinjak, 2013, izvirni znanstveni članek

Povzetek: Background. The aim of the study was evaluation of zoledronic acid with regard to safety, effect on analgesic consumption and impact on occurrence of skeletal related events in patients with bone lesions from solid tumors and multiple myeloma.Methods. We conducted an observational, 12-month, phase IV and multi-center study. One hundred and twenty-five symptomatic (pain) bone-metastatic patients were included between 2007 and 2009: 92 prostate cancers, 28 multiple myelomas, 5 others. They were prescribed monthly infusions of zoledronic acid in accordance to each diseases treatment guidelines. Analgesics consumption, pain and laboratory values were evaluated.Results. Zoledronic acid was prescribed concurrent to initial therapy for myeloma and only in late stage of prostate cancer. With treatment, percentage of patients on analgesics decreased in myeloma group (from 57% to 24%) and increased in prostate cancer group (from 70% to 88%). In patients with any analgesics, the use of opiates prescriptiondropped from 72.9% to 64%, percentages of non-steroidal analgesics and other mild analgesics increased slightly. Pain score (Visual Analog Scale, VAS) decreased non significantly (by 22%) in prostate cancer but significantly in myeloma (by 97%). Hypocalcaemia grade 3 or 4 was observed in 4% of patients. Deviations in creatinine remained stable throughout. A total of 31 skeletal related events were reported for 10 patients (8%).Conclusions. Zoledronic acid was safe medication. Different response of pain was seen between prostate cancer and myeloma patients, which might be due to different stages of disease where it was prescribed according to present guidelines. Possibility of earlier start of treatment should be explored in prostate cancer.
Objavljeno v DiRROS: 03.04.2024; Ogledov: 71; Prenosov: 23
.pdf Celotno besedilo (410,07 KB)

2.
Assessment of renal function from creatinine clearance measurement and 131I-hippuran renography in cancer patients before chemotherapy
Borut Štabuc, Tine Hajdinjak, Tomaž Edvard Cizej, 1999, izvirni znanstveni članek

Povzetek: Background. Serum creatinine and endogenous creatinine clearance (CrCl) are widely used measures of renal function before prescribing nephrotoxic chemotherapy. This study compares the precision and bias in glomerular filtration rate (GFR) estimation without the need to collect urine by using Cockcroft-Gault formula on a single serum creatinine concentration (CrCo) and 131I- hippuran clearance (HC) determined from the renographic curves. Patientsand methods. Fourty-seven patients aged between 27 and 73 years were studied. In all patients, we determined serum creatinine concentration, CrCl, CrCo and HC simultaneously before treatment by combined chemotherapy with cisplatin (CDDP) and in 31 patients, before the third cycle. Serum and urine creatinine concentrations were determined with a Hitachi 911, an automated biochemical analyser CrCl was calculated from the urine flow, from the ratio between the serum and urine creatinine concentrations and was standardized forthe body surface area. Serum creatinine was used to estimate CrCo using a Cockcroft and Gault formula. HC was determined from 131I-hippuran uptake by both kidneys, results were compared to our Nuclear Medicine Department normal values with regard to the age of each patient. For the evaluation of results, Pearson's correlation coefficient and t-test with 95 % confidence interval were used. Results. The sensitivity of serum creatinine, CrCo and HC to predict CrCl<78 mL/min/1.73m2 was 41 %, 68% and 46% and specificity was 95%, 71 % and 76% respectively. Value of CoCr for prediction of reduced CrCl (sensitivity) was statistically significantly better than the HC (p=0.03). Value of CoCr fnr prediction of normal CrCl (specificity) was as good as HC (p=0.3). Conclusions. CrCl for the GFR estimation in the patients treated withnephrotoxic chemotherapy cannot be changed by CrCo and/or HC.
Objavljeno v DiRROS: 22.01.2024; Ogledov: 172; Prenosov: 43
.pdf Celotno besedilo (463,87 KB)
Iskanje izvedeno v 0.07 sek.
Na vrh